American Association for Cancer Research
Browse

Supplementary Figure 6 from Stress Chaperone Mortalin Contributes to Epithelial-to-Mesenchymal Transition and Cancer Metastasis

Download (253.99 kB)
figure
posted on 2023-03-31, 00:12 authored by Youjin Na, Sunil C. Kaul, Jihoon Ryu, Jung-Sun Lee, Hyo Min Ahn, Zeenia Kaul, Rajkumar S. Kalra, Ling Li, Nashi Widodo, Chae-Ok Yun, Renu Wadhwa
<p>Correlation of mortalin amplification with other genes involved in human carcinogenesis. (A) Network showing correlation of mortalin amplification in Kidney Renal Clear Cell Carcinoma (RCCC, TCGA database) with other genes is shown. (B) Amplification of mortalin locus showed tight association and mutual exclusiveness with FGF1 and p53, respectively.</p>

History

ARTICLE ABSTRACT

Mortalin/mthsp70 (HSPA9) is a stress chaperone enriched in many cancers that has been implicated in carcinogenesis by promoting cell proliferation and survival. In this study, we examined the clinical relevance of mortalin upregulation in carcinogenesis. Consistent with high mortalin expression in various human tumors and cell lines, we found that mortalin overexpression increased the migration and invasiveness of breast cancer cells. Expression analyses revealed that proteins involved in focal adhesion, PI3K–Akt, and JAK–STAT signaling, all known to play key roles in cell migration and epithelial-to-mesenchymal transition (EMT), were upregulated in mortalin-expressing cancer cells. We further determined that expression levels of the mesenchymal markers vimentin (VIM), fibronectin (FN1), β-catenin (CTNNB1), CK14 (KRT14), and hnRNP-K were also increased upon mortalin overexpression, whereas the epithelial markers E-cadherin (CDH1), CK8 (KRT8), and CK18 (KRT18) were downregulated. Furthermore, shRNA-mediated and pharmacologic inhibition of mortalin suppressed the migration and invasive capacity of cancer cells and was associated with a diminished EMT gene signature. Taken together, these findings support a role for mortalin in the induction of EMT, prompting further investigation of its therapeutic value in metastatic disease models. Cancer Res; 76(9); 2754–65. ©2016 AACR.